Nifedipine Inhibition of High-Voltage Activated Calcium Channel Currents in Cerebral Artery Myocytes Is Influenced by Extracellular Divalent Cations.

Voltage-dependent calcium channels (VDCCs) play an essential role in regulating cerebral artery diameter and it is widely appreciated that the L-type VDCC, Ca1.2, encoded by the CACNA1C gene, is a principal Ca entry pathway in vascular myocytes. However, electrophysiological studies using 10 mM extracellular barium ([Ba]) as a charge carrier have shown that ~20% of VDCC currents in cerebral artery myocytes are insensitive to 1,4-dihydropyridine (1,4-DHP) L-type VDDC inhibitors such as nifedipine. Here, we investigated the hypothesis that the concentration of extracellular divalent cations can influence nifedipine inhibition of VDCC currents. Whole-cell VDCC membrane currents were obtained from freshly isolated rat cerebral artery myocytes in extracellular solutions containing Ba and/or Ca. In the absence of [Ca], both nifedipine-sensitive and -insensitive calcium currents were observed in 10 mM [Ba]. However, VDCC currents were abolished by nifedipine when using a combination of 10 mM [Ba] and 100 μM [Ca]. VDCC currents were also completely inhibited by nifedipine in either 2 mM [Ba] or 2 mM [Ca]. The biophysical characteristics of all recorded VDCC currents were consistent with properties of a high-voltage activated VDCC, such as Ca1.2. Further, VDCC currents recorded in 10 mM [Ba] ± 100 μM [Ca] or 2 mM [Ba] exhibited similar sensitivity to the benzothiazepine L-type VDCC blocker, diltiazem, with complete current inhibition at 100 μM. These data suggest that nifedipine inhibition is influenced by both Ca binding to an external site(s) on these channels and surface charge effects related to extracellular divalent cations. In sum, this work demonstrates that the extracellular environment can profoundly impact VDCC current measurements.